Nomura Holdings’s Viridian Therapeutics VRDN Stock Holding History

Nomura Holdings’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.84M	Buy	+100,200	New	+$1.61M	﹤0.01%	1152

Other funds holding VRDN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nomura Holdings's VRDN Position: Q2 2026 in Review

Nomura Holdings sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 22,205 shares — an estimated $358K sold.

Nomura Holdings first reported a position in VRDN in Q4 2015 and held it in 2 quarters. The position peaked at $434K in Q1 2026. 193 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Nomura Holdings reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
Nomura Holdings sold 22,205 Viridian Therapeutics shares in Q2 2026, an estimated $358K.
Nomura Holdings first reported a position in Viridian Therapeutics in Q4 2015 and held it in 2 quarters.
Nomura Holdings's Viridian Therapeutics position peaked at $434K in Q1 2026.
193 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.